The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...

The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

An inquest has opened into the death of a building contractor who collapsed at a property in Islip Road in Oxford.

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Researchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...